Budget 2025 Cuts Intelligence Watchdog Funds
Canada's 2025 federal budget reveals significant cuts to intelligence oversight agencies, raising concerns about transparency and accountability in national security operations.
Canada's 2025 federal budget reveals significant cuts to intelligence oversight agencies, raising concerns about transparency and accountability in national security operations.
Alberta's government is launching a search for a new Auditor General while current AG Doug Wylie offers to extend his term for two more years, creating political tension and uncertainty around financial oversight.
The Canadian Public Accountability Board appoints Sonny Randhawa as new CEO, bringing extensive financial regulation experience to strengthen audit oversight across Canada.
The FDA's principal deputy commissioner, Dr. Namandjé Bumpus, resigns following federal probe into undisclosed concerns about her conduct, marking significant leadership shakeup.
Ardena strengthens its leadership with strategic hires of Chief Quality Officer and Chief Information Officer to drive operational excellence and digital transformation in pharmaceutical services.
In a landmark move reshaping the consumer healthcare landscape, Kimberly-Clark announces its acquisition of Kenvue, the company behind Tylenol and other household brands, in a staggering US$48.7 billion transaction that creates a new industry powerhouse.
In a landmark healthcare deal, Kimberly-Clark acquires Kenvue, the consumer health giant behind Tylenol, Band-Aid and Listerine, reshaping the North American healthcare landscape.
Health Canada issues urgent recall for specific blood pressure medications containing potentially carcinogenic nitrosamine impurity. Learn which lots are affected and what steps to take.
Pharmaceutical giant Eli Lilly reports explosive growth driven by Mounjaro and Zepbound, creating intense investor competition and reshaping the obesity treatment landscape.
Pharmaceutical giants and startups race to develop next-generation weight-loss treatments as demand soars and market valuations skyrocket in this healthcare revolution.
Global pharmaceutical leader Boehringer Ingelheim secures exclusive license from Kyowa Kirin to develop innovative autoimmune disease treatment, targeting conditions like lupus and rheumatoid arthritis with novel therapeutic approach.
A former Melita pharmacy manager faces consequences after being convicted of multiple professional misconduct charges, including improper prescription practices and record-keeping failures.